177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
about
Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide TherapyLongitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatmentBiokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a reviewProduction of (177)Lu for Targeted Radionuclide Therapy: Available Options.Paragangliomas and paraganglioma syndromes.MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapyEstimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphySubacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN 177LU-DOTATATE TREATMENTS.Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotateA Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin AnalogsAccuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.Yttrium-labelled peptides for therapy of NET.Lutetium-labelled peptides for therapy of neuroendocrine tumours.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy.Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of lifeLong-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT systemPeptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.The role of patient-based treatment planning in peptide receptor radionuclide therapy.Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.Patient dosimetry in nuclear medicine.The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment.Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study.Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools.
P2860
Q26768478-24979E93-AE1A-4248-B0DB-DFE600A75BD3Q30828860-35AC2515-330B-4EAF-B775-7F59A8088821Q33737587-101C9292-900E-4E22-917A-1AF9672E8E73Q34157391-7BBBBEBF-45B5-4218-8E23-D316D8C178FEQ35244181-9D4AB13B-9DE3-41CC-8877-70FE7B7AA5A9Q35556123-883EFDFC-A608-4EA5-94D3-B9F48F1BDD32Q35724907-64E998F6-739B-44F4-A69D-2A10BF298414Q35926265-E064D8F8-83CE-48FD-8B5D-004702AE6174Q36302205-73FB83CF-D44E-46C5-BBDA-4ACF68A008B5Q36423806-9DCF20A9-7B02-43D6-BAD7-B91F912E820FQ36516035-7E655535-AAF4-461B-BDD6-F6F478ABA28AQ36942728-563B76E5-19EC-444D-BD30-68D4E65C41FDQ37016021-C3F6762E-E26E-4A2E-93C3-1E5C76526B00Q37143853-EAFE37E6-8FD4-4534-8A26-F9CC50F7CBA0Q37164623-CA71F8A9-653A-4C57-A521-0A879DD6DC67Q37608115-CBF84DFA-26F6-4AD1-8463-80790983F015Q37990401-131E72AE-0F73-4330-9BAF-835D757B29E6Q37990411-84F83DF8-0668-448A-923E-9BE8724090DEQ38271733-778A932C-DEED-43A6-AFA9-FF1D9A6AECA0Q38753821-A60EE875-0C6C-4C76-88A3-003BC6087D96Q38756968-A567E6F1-3850-4116-B433-BFF31C4724F2Q38870046-5A701B27-A5C5-47E7-A2E6-7701A1F6F5D1Q38884776-4B51B122-0180-465D-9F9C-0B71CC0E6712Q38898323-0A4133A2-3931-43D2-B41B-CAFA4F72E7FAQ38909078-72C8529E-8007-4B0D-86BA-5F6ECE70EB2FQ39183360-2079A6DB-B79D-4176-9F41-321B0B46F9B7Q39430065-A981C4DE-9312-4A82-9F82-22870AC6966DQ40311407-7921418A-1079-4CF0-B337-5D8F6422550FQ40676597-DD332811-91FD-4701-BD2B-20F1540E8A7DQ41142775-C6910F82-3536-4E66-A2D5-2A864E3DF679Q41192086-23BE9F80-42B2-4328-9803-5AEF127A9584Q42345704-488B0D88-9FFA-4B54-8DA2-F3C29A66D873Q43100704-BC783C74-AEB2-4188-AD86-C2A0DA708264Q47163935-B579332D-1CF2-46EC-97E0-792E1489F3B2Q47680976-A3795F6E-FA87-446E-888D-7A580543016CQ52677878-551BC834-9A23-4BE6-B15F-2A6C63026998Q52982765-DF52690E-B92D-457D-96EC-ED3E310DF4F3Q53163035-9FB379EB-55FC-450F-9184-A3BDCCB835FEQ53213092-058B46D4-9F58-42D3-9467-020CB2B1A6D6Q54193722-F1F10EEF-A9CB-41B2-ACAC-4A410EDDF634
P2860
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@en
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@nl
type
label
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@en
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@nl
prefLabel
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@en
177Lu-[DOTA0,Tyr3] octreotate ...... n future therapeutic strategy.
@nl
P2093
P356
P1433
P1476
177Lu-[DOTA0,Tyr3] octreotate ...... on future therapeutic strategy
@en
P2093
Jan Tennvall
Karin Wingårdh
Mattias Nickel
Michael Garkavij
Michael Ljungberg
Sven-Erik Strand
Tomas Ohlsson
P304
P356
10.1002/CNCR.24796
P407
P433
P577
2010-02-01T00:00:00Z